Can correcting the ΔF508-CFTR Proteostasis-Defect rescue | 22216
Pediatrics & Therapeutics

Pediatrics & Therapeutics
Open Access

ISSN: 2161-0665

Can correcting the ΔF508-CFTR Proteostasis-Defect rescue CF lung disease?

International Conference on Pediatrics & Gynecology

6-8 December 2011 Philadelphia Airport Marriott, USA

Neeraj Vij

Scientific Tracks Abstracts: Pediatr Therapeut

Abstract :

Protein homeostasis (proteostasis) generates and maintains individual proteins in their folded and functional-competent states. Th e components of the cellular proteostasis machinery also dictate the functional lifetime of a protein by constantly regulating its conformation, concentration and subcellular location. Th e autosomal recessive disease cystic fi brosis (CF) is caused by a proteostasis-defect in CF transmembrane conductance regulator (CFTR). Th e most common CF mutation leading to this proteostasis-defect is the deletion of a phenylalanine residue at position 508 (�?�?F508) of the CFTR protein. Th is �?�?F508-CFTR protein is prone to aberrant folding, increased ER-associated degradation, atypical intracellular traffi cking, and reduced stability at the apical membrane. Th us �?�?F508-CF proteostasis-defect leads to an obstructive lung disease characterized by impaired ion transport in airway epithelial cells, mucus buildup in air space and chronic airway infl ammation. We assess here if correcting the underlying defect in �?�?F508-CFTR protein processing by therapeutic proteostasis regulator can treat chronic CF lung disease. As a proof of concept, recent studies support that the selective modulation of mutant CFTR proteostasis may off er promising therapies to reverse chronic CF lung disease. Although to quantify the effi cacy of therapeutic strategies that not only correct the �?�?F508-CF proteostasis-defect but also chronic lung disease, pulmonary function tests and state of the art molecular imaging technologies that evaluate the state of lung disease need to be utilized. Th is will lead to the identifi cation of novel therapeutics that can correct �?�?F508-CFTR�s underlying proteostasis-defect to treat the obstructive lung disease.

Biography :

Dr. Neeraj Vij is an Assistant Professor at Department of Pediatric Respiratory Sciences and Institute of NanoBiotechnology, Th e Johns Hopkins University. Dr. Vij obtained his PhD in Biotechnology from Indian Institute of Technology, India in 2001 followed by postdoctor al fellowships at Institute of Genetics, BRC, Hungary, University of Heidelberg, Germany and Johns Hopkins University, USA. He joined Johns Hopkins faculty in 2006 and his major research interests includes in fl ammatory and protein misfolding disorders. The research focus of his laboratory is identi fi cation of molecular pathways leading to chronic disease pathophysiology with an aim to identify novel therapeutic sites. At the translational front his laboratory focuses on identi fi cation of novel therapeutic strategies including design of small molecules and nano- drug delivery systems.